HER2-NEGATIVE BREAST CANCER

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-phase trial is testing a new drug called BGB-21447, which blocks a protein that helps cancer cells survive. It is given together with standard hormone therapy (fulvestrant) and sometimes another targeted drug (BGB-43395). The study involves 120 adults with HR+/HER2- me…

This study is testing many different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. Researchers are looking at which combinations work best for different cancer types, such as triple-negative or hormone receptor-positive…

This study tests whether adding two immunotherapy drugs (CDX-1140 and CDX-301) to standard chemotherapy (PLD) is safe and helps control metastatic HER2-negative breast cancer. About 30 people with advanced cancer that has not responded to other treatments will take part. The goal…

This early-phase trial is testing leflunomide, a drug currently used for rheumatoid arthritis, in people with advanced solid tumors that have a PTEN gene change or HER2-negative breast cancer. The study has two parts: first, finding a safe dose and checking for side effects; seco…

This early-phase study tests a new drug, ASP2998, that targets a protein called TROP2 found on many solid tumors. The drug is given alone or with standard treatments like pembrolizumab or carboplatin. The main goals are to check safety and find the right dose. About 428 adults wi…

This study compares a combination of two drugs (elacestrant and capecitabine) to capecitabine alone in people with advanced estrogen receptor-positive breast cancer that no longer responds to CDK 4/6 inhibitors. About 297 participants will be randomly assigned to one of the two t…

This study tests a combination of two drugs—elacestrant and trastuzumab deruxtecan—in people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultralow) that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The goal is to find the s…

This study compares two drug combinations for people with a type of advanced breast cancer (HR+/HER2-) that has a specific genetic change (PIK3CA mutation) and has worsened after prior treatment. About 540 adults will receive either the experimental drug RLY-2608 plus fulvestrant…

This early-phase trial is testing an experimental oral drug called RGT-490 in about 63 adults with advanced solid tumors (including certain breast, ovarian, and endometrial cancers) that have a PIK3CA gene mutation and have stopped responding to standard treatments. The main goal…

This study looks at whether giving hormone therapy before breast-conserving surgery helps reduce leftover cancer cells at the edges of removed tissue. It involves 176 postmenopausal women with stage 2-3 ER+/HER2- invasive lobular carcinoma. The goal is to see if this approach lea…

This phase 2 trial is testing a combination of three drugs—alpelisib, L-NMMA, and nab-paclitaxel—in people with a rare, aggressive form of breast cancer called metaplastic breast cancer (MpBC) that has spread or is locally advanced. The study aims to find the best dose and see if…

This phase 2 study is testing a drug called sacituzumab govitecan, alone or with pembrolizumab, given before surgery to people with localized triple-negative breast cancer. The goal is to see if these drugs can eliminate all cancer cells in the breast and lymph nodes before surge…

This early-stage trial tests the drug abemaciclib (a CDK4/6 inhibitor) given together with targeted radiation for people with metastatic HR+ HER2- breast cancer that has spread to bone. The main goal is to find the safest dose of abemaciclib when combined with radiation. About 28…

This Phase 2 trial at Fudan University tests several targeted drug combinations given before surgery for early-stage breast cancer. The goal is to see which combinations best eliminate all signs of cancer (pathological complete response) based on each tumor's specific subtype. Ab…

This study is for people with a common type of breast cancer (ER-positive, HER2-negative) that has a moderate to high risk of coming back based on tumor size and lymph node involvement, but a low genetic risk score. Instead of chemotherapy after surgery, participants can choose t…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This Phase 3 trial tests whether elacestrant, a new hormone therapy, can prevent distant metastasis better than standard hormone therapies in 220 patients with ER+/HER2- breast cancer whose blood tests show signs of cancer DNA (ctDNA) but no visible spread. Participants are rando…

This study tests different hormone therapies in men with breast cancer before they have surgery. The goal is to see which treatment works best to shrink the tumor. About 60 men with hormone receptor-positive breast cancer will take part.

This phase 2 trial is testing whether the drug elacestrant, given alone or with triptorelin (which temporarily stops ovary hormone production), can slow or shrink hormone-sensitive breast tumors in premenopausal women. About 96 women will take the pills daily for 30 days before t…

This pilot study is testing whether a device called TheraBionic P1, which delivers targeted electromagnetic fields, can affect breast cancer tumors before surgery. About 24 women with early-stage, hormone receptor-positive, HER2-negative breast cancer will use the device three ti…

This study tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy can help shrink tumors or slow disease in people with advanced HER2-negative breast cancer. About 92 adults whose cancer has worsened after prior treatments will receive the combinat…

This study tests whether giving a different antibody-drug conjugate (ADC) to people with advanced breast cancer who have already tried an ADC can still shrink tumors or slow the disease. About 160 participants will receive one of several ADCs or a targeted pill. The goal is to se…

This study is for people with a type of breast cancer (hormone receptor-positive, HER2-negative) that has come back in the same area after initial treatment. The goal is to see if adding the drug ribociclib to standard hormone therapy can help prevent the cancer from returning ag…

This study tests whether adding everolimus to elacestrant can help people with a certain type of advanced breast cancer (ER+/HER2- with an ESR1 mutation) live longer without their cancer getting worse. About 240 adults whose cancer has stopped responding to standard hormone thera…

This study tests whether a combination of three drugs (anastrozole, fulvestrant, and abemaciclib) can shrink or control tumors in people with a common type of advanced breast cancer (hormone receptor positive, HER2-negative). About 20 participants whose cancer has spread or retur…

This phase 3 study tests whether adding capivasertib to standard hormone therapy helps people with HR+/HER2- advanced breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib plu…

This study is testing whether adding two drugs (anlotinib and a tubulin inhibitor) to standard radiation therapy can help control HER2-negative breast cancer that has spread to the brain. About 39 women aged 18-70 will receive radiation followed by the drug combination. The main …

This early-phase study tests an experimental vaccine made from a patient's own immune cells, designed to target two cancer-related proteins (HER2 and HER3). The vaccine is injected directly into the tumor alongside standard chemotherapy before surgery. The goal is to find the saf…

This study tests a new drug called SPR1020 in adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to target cancer cells with specific genetic changes (BRCA or HRR mutations) and may also reach brain tumors. The goal is to find a…

This early-stage trial is testing a combination of two chemotherapy drugs (melphalan and BCNU) plus vitamins B12b and C, followed by an infusion of the patient's own stem cells. The goal is to see if this approach is safe for people with metastatic pancreatic or breast cancer, es…

This study tests a combination of two drugs, fulvestrant and abemaciclib, for people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to a first-line treatment called a CDK4/6 inhibitor. The goal is to see if taking a break fr…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This study tests whether a blood test (ctDNA) can identify women with early-stage, hormone-positive breast cancer who can safely avoid chemotherapy. Instead of chemo, they receive a targeted pill (dalpiciclib) plus hormone therapy before surgery. The goal is to reduce side effect…

This Phase I trial is testing a new drug called BL-M17D1 in 20 people with advanced breast cancer (HER2-positive or negative) or other solid tumors that have spread. The main goals are to check the drug's safety, find the right dose, and see early signs of whether it shrinks tumo…

This study tests whether tirzepatide, a drug used for weight loss, can help patients with early-stage hormone receptor-positive, HER2-negative breast cancer lose at least 5% of their body weight during adjuvant treatment. The trial will enroll 40 adults and also check safety, sid…

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

This study tests whether adding bevacizumab to standard chemotherapy before surgery can improve outcomes for people with early or locally advanced HER2-negative breast cancer. About 75 participants will receive the drug combination, and researchers will measure how many achieve a…

This early study tests whether combining a special immune-boosting vaccine (DC1) with the drug elacestrant is safe and doable for people with a common type of advanced breast cancer (HR+ HER2-). About 18 participants will receive the treatment for 8 weeks. The goal is to see if t…

This study is for people with HER2-negative breast cancer that has spread to the lining of the brain (leptomeningeal metastasis). It compares standard chemotherapy given through the veins or by mouth to the same treatment plus extra chemotherapy delivered directly into the spinal…

This study tests whether adding retinoic acid (a vitamin A derivative) to an immune checkpoint inhibitor can help shrink tumors or slow disease progression in people with HER2-negative breast cancer whose cancer stopped responding to prior immunotherapy. About 10 participants wil…

This study tests whether giving radiation again after a second lumpectomy is safe for women with a common type of breast cancer (ER+HER2-). About 114 women who had radiation before and whose cancer came back at least 18 months later will receive targeted radiation over 3 weeks. T…

This study tests whether a daily pill (Z-endoxifen) plus a monthly shot (goserelin) can slow or stop estrogen-driven breast cancer growth in premenopausal women. About 87 participants will take the drugs for up to 24 weeks before surgery. The main goal is to see if the treatment …

This phase 2 trial is testing two antibody-drug conjugates—trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan (Dato-DXd)—in people with HER2-negative metastatic breast cancer whose disease has worsened after prior antibody-drug conjugate therapy. Participants will receiv…

This early-phase study tests a new drug called OP-1250 (palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find safe doses and check for side effects. About 190 adults will joi…

This phase II trial tests two experimental drugs, SI-B003 and BL-B01D1, in people with advanced HER2-negative breast cancer that has not responded to standard treatments. The study will see if the drugs can shrink tumors and determine the best dose. About 58 participants will rec…

This early-stage study is testing a new drug called RLY-2608, which is designed to block a specific mutant protein (PIK3CA) that helps some cancers grow. The trial includes people with advanced solid tumors or breast cancer that has not responded to other treatments. Participants…

This study tests whether giving a single dose of radiation during breast-conserving surgery works as well as standard weeks-long radiation for early-stage, HER2-negative breast cancer. About 620 women aged 55 and older will take part. The goal is to see if this approach lowers th…

This study tests a new imaging system that uses light to monitor how breast cancer responds to chemotherapy before surgery. Researchers want to see if it can accurately predict when the cancer is completely gone. The study involves 15 women with specific types of breast cancer. I…

This study is testing whether a special PET/CT scan that looks for a protein called PSMA can help predict resistance to anti-androgen therapy in people with a specific type of metastatic breast cancer (HER2-negative, AR-positive). About 13 participants will receive an injection o…

This study is looking at whether a blood test called DiviTum TKa can predict when hormone-receptor-positive, HER2-negative metastatic breast cancer stops responding to treatment. About 100 participants will give blood samples before and during their standard therapy. The goal is …

This early-phase study looks at whether adding dapagliflozin, a diabetes drug, to standard chemotherapy changes insulin-related markers in the blood. It involves 20 women with early-stage HER2-negative breast cancer who also have high insulin levels. The goal is to gather safety …

This study aims to understand why some breast cancer patients experience 'chemobrain'—problems with memory, concentration, and thinking after chemotherapy. Researchers will track 50 patients before, during, and after chemo using brain scans, blood tests, and thinking tests. They …

This study is testing new drug combinations for breast cancer to see which ones work best for different tumor types. It involves up to 5,000 people with early-stage or locally advanced breast cancer. Researchers use MRI scans and tissue samples before surgery to predict treatment…

This study tests whether a decision aid and training for surgeons can help women aged 70 and older with low-risk stage I breast cancer make better treatment choices. About 402 participants will be split into two groups: one where surgeons get shared decision-making training and p…

This study is looking at a genomic test called EndoPredict that analyzes tumor genes to predict the risk of breast cancer returning. The goal is to see if women with a low-risk score can safely skip chemotherapy and only take hormone therapy. Researchers will follow 1,000 patient…

This study will follow 319 women with early-stage, hormone-sensitive, HER2-negative breast cancer to see how well they take their prescribed aromatase inhibitors, with or without the added drug abemaciclib. Researchers will measure adherence using pill counts and questionnaires a…

This study follows 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their routine care. Researchers will collect blood samples and medical records to see how long the cancer stays controlled with each ADC treatmen…